AstraZeneca (NASDAQ: AZN) reported Q1 EPS of $2.06, $1.10 better than the analyst estimate of $0.96. Revenue for the quarter came in at $12.68 billion versus the consensus estimate of $11.79 billion.

GUIDANCE

The Company reiterates its Total Revenue and Core EPS guidance for FY 2024 at CER, based on the average foreign exchange rates through 2023.

Total Revenue is expected to increase by a low double-digit to low teens percentage

Core EPS is expected to increase by a low double-digit to low teens percentage

Collaboration Revenue is expected to increase substantially, driven by success-based milestones and certain anticipated transactions

Other operating income is expected to decrease substantially (FY 2023 included a $241m gain on the disposal of Pulmicort Flexhaler US rights, and a $712m one-time gain relating to updates to contractual arrangements for Beyfortus)

The Core Tax rate is expected to be between 18-22%

For earnings history and earnings-related data on AstraZeneca (AZN) click here.